Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | AXL | P30530 | 11/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | MERTK | Q12866 | 10/20 | 0.37 |
| ▸ | MET | P08581 | 9/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 8/20 | 0.37 |
| ▸ | FYN | P06241 | 2/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CDK9 | P50750 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3114517 | 0.93 | AXL (0.40) | MAPK1AXLMERTKMETTYRO3 | |
| SCHEMBL3107657 | 0.93 | AXL (0.39) | AXLBRD4MERTKMETTYRO3 | |
| SCHEMBL3107510 | 0.88 | MET (0.41) | AXLMERTKMETTYRO3 | |
| SCHEMBL3112723 | 0.88 | AXL (0.37) | AXLMERTKMETTYRO3 | |
| SCHEMBL3112020 | 0.87 | MET (0.36) | AXLMERTKMETTYRO3 | |
| SCHEMBL3104399 | 0.85 | MET (0.40) | AXLMERTKMETTYRO3 | |
| SCHEMBL13101896 | 0.84 | AXL (0.52) | AXLMERTKMET | |
| SCHEMBL3106676 | 0.84 | BRD4 (0.39) | AXLBRD4MERTKMETTYRO3 | |
| SCHEMBL3109748 | 0.83 | LRRK2 (0.39) | AXLMERTKMETTYRO3 | |
| SCHEMBL3107037 | 0.82 | LRRK2 (0.41) | AXLBRD4CDK19MERTKMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | claimed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | MAPK1 241/4885AXL 117/4885BRD4 3330/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | MAPK1 241/4885AXL 117/4885BRD4 3330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.